Chad Harman, CEO of the company Psychaceutical on Neurodirect and Ketamine
In May 2023, I spoke with Chad Harman, the chief executive officer (CEO) of Psycheceutical. At 0:17, he described it as a bioscience company focused on mental health treatments, with psychedelic medicines as its lead compounds.